𝔖 Bobbio Scriptorium

✦ LIBER ✦

Combination therapy for treatment or prevention of atherosclerosis: Focus on the lipid-RAAS interaction

✍ Scribed by Koh, Kwang Kon (author);Han, Seung Hwan (author);Oh, Pyung Chun (author);Shin, Eak Kyun (author);Quon, Michael J. (author)

Book ID: 118422741
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 404 KB
Volume: 209
Category: Article
ISSN: 0021-9150
DOI: 10.1016/j.atherosclerosis.2009.09.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination therapy for treatment or pre

Combination therapy for treatment or prevention of atherosclerosis: Focus on the lipid-RAAS interaction

✍ Koh, Kwang Kon (author);Han, Seung Hwan (author);Oh, Pyung Chun (author);Shin, E 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 404 KB

Effects of Combination Lipid Therapy on

Effects of Combination Lipid Therapy on Coronary Stenosis Progression and Clinical Cardiovascular Events in Coronary Disease Patients With Metabolic Syndrome: A Combined Analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS)

✍ Xue-Qiao Zhao; Richard A. Krasuski; Jefferson Baer; Edwin J. Whitney; Blazej Ner 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 230 KB

Status of lipid-lowering therapy prescri

Status of lipid-lowering therapy prescribedbased on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: A study of the Japan Lipid Assessment Program (J-LAP)

✍ Tamio Teramoto; Atsunori Kashiwagi; Hiroshi Mabuchi; J-LAP Investigators 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 1015 KB

Niacin and Statin Combination Therapy fo

Niacin and Statin Combination Therapy for Atherosclerosis Regression and Prevention of Cardiovascular Disease Events: Reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Trial With Previous Surrogate Endpoint Trials

✍ Erin D. Michos; Christopher T. Sibley; Jefferson T. Baer; Michael J. Blaha; Roge 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 250 KB

On-Treatment Non–High-Density Lipoprotei

On-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy: JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)

✍ Samia Mora; Robert J. Glynn; S. Matthijs Boekholdt; Børge G. Nordestgaard; John 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 273 KB

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB